THE RESEARCH RECORD // FOUR SEPARATE EVIDENCE BASES
What the component literature has measured
The KLOW peptide research record, organized by the four arms of the blend. Each study attributed to the component it studied. The blend-level gap — zero controlled combination trials — is named first.
In plain English
The KLOW peptide research record is really four separate research records — one per component. KPV, GHK-Cu, BPC-157 and TB-500 have each been studied in their own right, in cells and in animals, and in a few early human contexts. What has not been studied is the combination: no controlled experiment has ever put all four together and measured what happens.
This page summarizes what each component's studies have actually found, mechanism by mechanism. Technical terms are explained in plain language when they first appear. Everything quantitative is cited. The evidence is real; the extrapolation to the blend is, for now, honest inference.
The combination gap
Before the component evidence: a clear statement of what does not exist. No controlled in-vivo or human study has tested the four-peptide KLOW blend — against monotherapy, against any two- or three-component subset, or against placebo. Every 'synergy' claim is mechanistic extrapolation from the single-component literature.
Additionally, a pharmacokinetic mismatch (the situation where compounds in the same vial clear at very different rates) is built into the design. BPC-157 has an elimination half-life under 30 minutes and intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs, with excretion via urine and bile [8]. The tripeptides KPV and GHK-Cu are smaller and clear faster still. A single co-formulated dose therefore cannot maintain all four components at matched tissue exposures.
With those structural limits stated plainly, the component findings follow.
BPC-157: tissue repair and the angiogenic pathway
BPC-157 (Body Protection Compound 157, a 15-amino-acid peptide derived from a protein identified in human gastric juice) is the angiogenic and tissue-repair arm of the KLOW blend.
In the landmark 2003 tendon study, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures at doses of 10 μg, 10 ng or 10 pg per rat (intraperitoneal, once daily), and stimulated tendocyte outgrowth in vitro [2]. In a 2006 study of Achilles detachment, BPC-157 promoted tendon-to-bone healing and opposed corticosteroid-induced aggravation [9]. A 2010 study demonstrated improved medial collateral ligament healing in rats across biomechanical, functional and microscopic measures [10]. A 2011 in vitro study established that BPC-157 promotes tendon healing at the cellular level by enhancing fibroblast outgrowth, survival and migration through the FAK-paxillin pathway (FAK = focal adhesion kinase, a signaling protein that mediates cell attachment and movement) [11].
The primary mechanism: VEGFR2 (vascular endothelial growth factor receptor 2, the angiogenic receptor) phosphorylation with downstream PI3K/Akt/eNOS activation, plus growth-hormone-receptor upregulation in tendon fibroblasts.
Pharmacokintically, BPC-157 shows linear kinetics, an elimination half-life under 30 minutes, and rapid breakdown into small peptide fragments entering normal amino-acid metabolism [8].
Recent reviews note the limitation: a 2025 narrative review (Curr Rev Musculoskelet Med) concluded that 'only three pilot studies have examined BPC-157 in humans' and recommends treating it as investigational [13]. The first formal human IV safety pilot (2025, n=2) administered BPC-157 at 10 mg and 20 mg intravenously and found no adverse events and no measurable changes in safety biomarkers [6].
TB-500: cytoskeletal mobility and wound closure
TB-500 is the synthetic heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, corresponding to the LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4 (Tbeta4). The distinction is important: most foundational efficacy data are for the full-length native Tbeta4, not the short TB-500 fragment.
The headline finding from the native protein: in a rat full-thickness wound model, topical or intraperitoneal thymosin β4 increased re-epithelialization (the process by which epithelial cells migrate to cover a wound surface) by 42% at 4 days and up to 61% at 7 days versus saline, with wound contraction increasing by at least 11% by day 7, and raised collagen deposition and angiogenesis [1]. As little as 10 pg stimulated keratinocyte migration 2–3-fold in cell migration assays [1].
The mechanism: the LKKTET motif sequesters G-actin (monomeric, globular actin held in reserve), a step linked to cell migration. Full-length Tbeta4 additionally activates integrin-linked kinase (ILK) and mobilizes epicardial progenitor cells — activities established for the native protein and not yet demonstrated for the TB-500 fragment.
A 2026 Sports Medicine review covering TB-500/thymosin β4 alongside BPC-157 in the context of musculoskeletal peptide therapies concluded that animal-model promise is not matched by rigorous human safety data [7].
KPV: inflammation suppression via PepT1
KPV is the tripeptide Lys-Pro-Val, corresponding to residues 11–13 of alpha-MSH (alpha-melanocyte-stimulating hormone). It is the anti-inflammatory arm of the KLOW blend.
The 2008 Dalmasso et al. study published in Gastroenterology is the primary mechanistic reference [3]. In human intestinal epithelial cell lines (Caco2-BBE and HT29-Cl.19A) and Jurkat T cells in vitro, nanomolar KPV (10 nM) inhibited NF-kB (nuclear factor kappa B, the transcription factor central to inflammatory gene expression) and MAPK (mitogen-activated protein kinase) inflammatory signaling and reduced secretion of TNF-α, IL-6, IL-1β and IL-8. KPV was transported into cells via PepT1 (SLC15A1, the intestinal di/tripeptide transporter with a Km of approximately 160 μM for KPV), which is upregulated in inflamed gut tissue — giving KPV a tissue-selective uptake advantage in inflamed epithelium. In C57BL/6 mice with DSS- and TNBS-induced colitis (two standard experimental models of intestinal inflammation), oral KPV at 100 μM in drinking water reduced colitis severity [3].
KPV has no approved human indication. Human data are limited to delivery pilots and its lineage in an inflammatory bowel disease research program.
GHK-Cu: matrix synthesis and transcriptomic breadth
GHK-Cu (Glycyl-L-Histidyl-L-Lysine complexed to a copper(II) ion, also known as Copper Tripeptide-1) is the mass-dominant component of the KLOW vial — approximately 50 of the canonical 80 mg, or about 62.5% by mass.
The skin-regeneration review (Pickart, Vasquez-Soltero and Margolina, BioMed Research International, 2015) summarized decades of clinical and in vitro work: GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin; plasma GHK declines from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60; and topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in a placebo-controlled clinical comparison, with documented improvements in skin laxity, fine lines and wrinkle depth [4].
The 2018 Pickart and Margolina gene-data review (IJMS) applied Connectivity Map analysis and found that GHK modulates expression of approximately 31.2% of human genes at a 50%-or-greater change threshold — increasing expression of 59% of affected genes and suppressing 41%, with the strongest signals on extracellular-matrix remodeling, the ubiquitin-proteasome system (41 genes up), and DNA-repair and antioxidant gene sets at concentrations of 1–10 nM [5].
GHK-Cu is the only KLOW component with robust published clinical data, though those data are in topical cosmetic and wound-healing applications rather than in the injectable context implied by research-vial use.
KLOW research
The full citation record with DOIs and PubMed links is on the KLOW references page.